NCT07188077Recruiting
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Based on Metabolomics and Immunomics
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 8 Sept 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Ting YANG
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07188077
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Mar 2025 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
- Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).
Other illness
- Presence of other systemic malignancies.
- Presence of severe infections or metabolic disorders.
- Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.
Other
- Pregnant or lactating women.
Who the study is looking for
- Aged between 18 and 75 years.
- The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
- Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
- Case group patients must have complete supporting imaging and pathology data.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.